Myostatin – The Holy Grail for Muscle, Bone, and Fat?
The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.
Abstract
Myostatin, a member of the transforming growth factor beta (TGF-β) superfamily, was first described in 1997. Since then, myostatin has gained growing attention because of the discovery that myostatin inhibition leads to muscle mass accrual. Myostatin not only plays a key role in muscle homeostasis, but also affects fat and bone. This review will focus on the impact of myostatin and its inhibition on muscle mass/function, adipose tissue and bone density/geometry in humans. Although existing data are sparse, myostatin inhibition leads to increased lean mass and 1 study found a decrease in fat mass and increase in bone formation. In addition, myostatin levels are increased in sarcopenia, cachexia and bed rest whereas they are increased after resistance training, suggesting physiological regulatory of myostatin. Increased myostatin levels have also been found in obesity and levels decrease after weight loss from caloric restriction. Knowledge on the relationship of myostatin with bone is largely based on animal data where elevated myostatin levels lead to decreased BMD and myostatin inhibition improved BMD. In summary, myostatin appears to be a key factor in the integrated physiology of muscle, fat, and bone. It is unclear whether myostatin directly affects fat and bone, or indirectly via muscle. Whether via direct or indirect effects, myostatin inhibition appears to increase muscle and bone mass and decrease fat tissue-a combination that truly appears to be a holy grail. However, at this time, human data for both efficacy and safety are extremely limited. Moreover, whether increased muscle mass also leads to improved function remains to be determined. Ultimately potential beneficial effects of myostatin inhibition will need to be determined based on hard outcomes such as falls and fractures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Its expression drops following weight loss because it directly influences adipocyte metabolism448, and myostatin inhibitors can directly inhibit muscle loss.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [448]
Citations
Cites
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256
Muscles, exercise and obesity: skeletal muscle as a secretory organ
Pedersen, B. K., & Febbraio, M. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.49 · Cited by 2,909
Sarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 1×
“Coincidentally, in the same year that myostatin was described, Rosenberg published an article titled “Sarcopenia: Origins and Clinical Relevance” describing how the term was coined in the late 1980s and the negative impact of sarcopenia on mobility, independence, falls, and fracture risk [31].”
BackgroundDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 2×
“They also found that Belgian Blue and Piedmontese cattle breeds, animals with a particularly large musclemass, both havemutations inmyostatin genes that lead to improperly functioning myostatin molecules [21].”
BackgroundMuscaritoli, M., Anker, S. D., Argilés, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., et al. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.12.004 · Cited by 1,732
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives
Rolland, Y., Czerwinski, S., van Kan, G. A., Morley, J. E., Cesari, M., Onder, G., Woo, J., Baumgartner, R., Pillard, F., Boirie, Y., et al. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02982704 · Cited by 1,071
Sarcopenic obesity: definition, cause and consequences
Stenholm, S., Harris, T. B., Rantanen, T., Visser, M., Kritchevsky, S. B., & Ferrucci, L. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328312c37d · Cited by 1,070
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Osteosarcopenia: where bone, muscle, and fat collide
Hirschfeld, H. P., Kinsella, R., & Duque, G. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4151-8 · Cited by 527
Muscle and bone, two interconnected tissues
Tagliaferri, C., Wittrant, Y., Davicco, M.-J., Walrand, S., & Coxam, V. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.03.002 · Cited by 390
Bone and muscle: Interactions beyond mechanical
Brotto, M., & Bonewald, L. (2015) · Bone · doi:10.1016/j.bone.2015.02.010 · Cited by 351
“The development of myostatin inhibitors was recently reviewed and has further stimulated the discussion around tissue crosstalk (56).”
BackgroundQin, Y., Peng, Y., Zhao, W., Pan, J., Ksiezak-Reding, H., Cardozo, C., Wu, Y., Divieti Pajevic, P., Bonewald, L. F., Bauman, W. A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.770941 · Cited by 278
Metadata
- Authors
- Buehring, B., & Binkley, N.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Buehring, B.
- Venue
- Current Osteoporosis Reports
- Published
- 2013-09-27
- Volume
- 11
- Issue
- 4
- Pages
- 407-414
- ISSN
- 1544-1873 (ISSN-L)
- 1544-2241
- OpenAlex
- W2008990345
- Cited by
- 79
- References
- 84
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 11 · 2016: 2 · 2015: 5 · 2014: 10
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Osteoporosis Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- myostatin, myostatin inhibition, muscle mass, muscle function, bone mineral density, bone geometry, adipose tissue, fat mass, lean body mass, sarcopenia, cachexia, resistance training, obesity, caloric restriction, TGF-beta superfamily
- MeSH terms
- Adipose Tissue, Animals, Bone and Bones, Humans, Muscles, Obesity, Osteoporosis, Signal Transduction, Myostatin, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myostatin – The Holy Grail for Muscle, Bone, and Fat? https://app.cochat.ai/papers/10.1007/s11914-013-0160-5
- The paper
- Buehring, B., & Binkley, N. (2013). Myostatin – The Holy Grail for Muscle, Bone, and Fat? Current Osteoporosis Reports. https://doi.org/10.1007/s11914-013-0160-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.